Supratek Pharma Inc.

Montréal, Canada

Supratek Pharma Inc.

Montréal, Canada

Time filter

Source Type

— Esophageal Cancer - Pipeline Market Review, H1 2017 is a new report added to ReportsnReports.com. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 85 Tables and 11 Figures, 16 Company Profiles, Spread across 493 Pages Report Available at http://www.reportsnreports.com/reports/992867-esophageal-cancer-pipeline-review-h1-2017.html . Drug Profiles of Esophageal Cancer - 1-BB1, ADCT-502, ADXS-HER2, afatinib dimaleate, AL-3818, ALM-301, apatinib, APR-246, atezolizumab, ATL-101, BGBA-317, binimetinib, brontictuzumab, CBT-501, CDX-1401 many more. Main Companies are Adaptimmune Therapeutics Plc, ADC Therapeutics Sar, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC , Almac Discovery Ltd, Amgen Inc , Aprea AB , ArQule Inc , Array BioPharma Inc , Aslan Pharmaceuticals Pte Ltd , ATLAB Pharma SAS , Bayer AG , BeiGene Ltd , Beta Pharma Inc , Boehringer Ingelheim GmbH , Bristol-Myers Squibb Company , CBT Pharmaceuticals Inc , Celgene Corp , Celldex Therapeutics Inc, Cellectar Biosciences Inc, CellSeed Inc , Clovis Oncology Inc , Cyclacel Pharmaceuticals Inc , Eli Lilly and Company , F. Hoffmann-La Roche Ltd , Genmab A/S , GlaxoSmithKline Plc, Glycotope GmbH , Hutchison China MediTech Ltd , Ignyta Inc , Immunocore Ltd, ImmunoFrontier Inc , Immunomedics Inc , Intezyne Technologies Inc , Jiangsu Hengrui Medicine Co Ltd , Johnson & Johnson , Komipharm International Co Ltd , Leap Therapeutics Inc , MaxiVAX SA , Mebiopharm Co Ltd , MedImmune LLC , Merck & Co Inc , Novartis AG , Omeros Corp , Oncolys BioPharma Inc , OncoMed Pharmaceuticals Inc , Ono Pharmaceutical Co Ltd , Puma Biotechnology Inc, Rhizen Pharmaceuticals SA , Shionogi & Co Ltd , Spectrum Pharmaceuticals Inc , Stelic Institute & Co Inc , Supratek Pharma Inc 63, Symphogen A/S 63, Taiho Pharmaceutical Co Ltd 64, Taiwan Liposome Company Ltd 64, Takara Bio Inc 65, Transgene Biotek Ltd 65, VioQuest Pharmaceuticals Inc 66, XuanZhu Pharma Co Ltd. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992867. Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery. The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 6, 33, 28, 2, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 5, 2 and 1 molecules, respectively. Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology). • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the For more information, please visit http://www.reportsnreports.com/reports/992867-esophageal-cancer-pipeline-review-h1-2017.html


Valle J.W.,Christie Hospital NHS Trust | Valle J.W.,University of Manchester | Armstrong A.,Christie Hospital NHS Trust | Newman C.,Supratek Pharma Inc. | And 8 more authors.
Investigational New Drugs | Year: 2011

Purpose:To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastro-esophageal junction (GEJ). Patients and Methods: Patients with metastatic or locally advanced unresectable adenocar-cinoma of the esophagus or GEJ who had not previously received systemic chemotherapy and had measurable disease were treated with SP1049C 75 mg/m 2 (doxorubicin equivalents) as a brief intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate in patients who had received a least one course of SP1049C and had undergone tumor assessment, whereas, secondary endpoints included the objective response rate, progression-free survival (PFS), overall survival, and safety in the intent-to-treat (ITT) population. A review of scans was also conducted post-hoc by a blinded panel of radiologists. Results: Twenty-one patients, of which 19 were evaluable for response, were treated with at least one dose of SP1049C. Nine patients had a partial response (PR) and eight patients had either a minor response or stable disease as their best response. The objective response rate was 47% (95% CI:24.4-71) in the evaluable patient population, whereas the objective response rate was 43% (95% CI:21.8-65.9) in the ITT population. The post-hoc radiological review confirmed that all nine responders had a PR; seven of the nine had a PR that was confirmed by a subsequent scan, whilst two patients had unconfirmed PRs. The median overall survival and PFS were 10.0 months (95%CI:4.8-11.2) and 6.6 months (95% CI:4.5-7.6), respectively. Neutropenia was the principal toxicity of SP1049C. Four patients developed an absolute percentage decrement of at least 15% in their left ventricular ejection fraction, none of which decreased to below 45% nor were symptomatic. Conclusion: SP1049C has a notable single-agent activity in patients with adenocarcinoma of the esophagus and GEJ, as well as an acceptable safety profile. These results, in addition to the results of preclinical studies demonstrating superior antitumor activity of SP1049C compared with doxorubicin in a standard formulation, indicate that further evaluations of SP1049C alone or combined with other relevant therapeutics in this disease setting are warranted. © Springer Science+Business Media, LLC 2010.


Semov A.,Supratek Pharma Inc. | Iourtchenco L.,Supratek Pharma Inc. | Lin Fang L.,Supratek Pharma Inc. | Shengmin L.,Supratek Pharma Inc. | And 5 more authors.
Biochemical and Biophysical Research Communications | Year: 2012

Epidemiologic studies repeatedly have shown chemopreventive effects of cruciferous vegetables. Indole-3-carbinol (I3C) and its metabolite diindolylmethane (DIM) were identified in these plants as active ingredients and theirs anti-tumor activities were confirmed in multiple in vitro and in vivo experiments. Here, we demonstrate that DIM is a selective and potent inhibitor of cancer stem cells (CSCs). In several cancer cell lines, DIM inhibited tumor sphere formation at the concentrations 30-300 times lower than concentrations required for growth inhibition of parental cells cultured as adherent culture. We also found that treatment with DIM overcomes chemoresistance of CSCs to cytotoxics, such as paclitaxel, doxorubicin, and SN-38. Pre-treatment of tumor spheres with DIM before implantation to mice significantly retarded the growth of primary tumors compared to tumors formed by untreated tumor spheres. The concentrations of DIM required to suppress CSCs formation are in the close range to those achievable in human plasma after oral dosing of the compound. Therefore, DIM can potentially be used in cancer patients, either alone, or in combinations with existing drugs. © 2012 Elsevier Inc.


Kiselev V.,RAS Research Center Kurchatov Institute | Klinskiy E.,Supratek Pharma Inc | Lee S.,Supratek Pharma Inc | Muyzhnek E.,MiraxBioPharma | And 2 more authors.
Journal of Nanomedicine and Nanotechnology | Year: 2013

At the present, a high potential of 3,3'-diindolylmethane (DIM) as a new preventive and therapeutic agent in oncology is well established, due to its ability to target multiple components of cancer cell cycle regulation, survival and progression. However, a very low bioavailability of DIM remains the major challenge for its efficient development as novel medicine. In this work, we have developed a polymer based nano-formulation comprising a non-ionic block copolymer, Pluronic F127 that increases oral bioavailability of DIM by almost one order of magnitude, as compared to the presently marketed products such as crystalline DIM and BioResponse DIM. The pharmacokinetic parameters established in the present study revealed that AUC and Cmax of the new formulation dosed at 60 mg/kg were 7.06 ± 0.93 μg · h/mL, and 3.08 ± 0.17 μg/mL, while in the case of crystalline DIM dosed at the same dose AUC and Cmax were 0.97 ± 0.08 μg · h/mL, and 0.18 ± 0.02 μg/mL. BioResponce DIM showed AUC and Cmax of 1.05 ± 0.05 μg · h/mL, and 0.22 ± 0.02 μg/mL, respectively. © 2013 Kiselev V, et al.

Loading Supratek Pharma Inc. collaborators
Loading Supratek Pharma Inc. collaborators